COLLABORATION, LICENSE AND OTHER STRATEGIC AGREEMENTS (Details) - USD ($)			1 Months Ended			3 Months Ended			6 Months Ended	12 Months Ended
	Jan. 16, 2019	Apr. 03, 2017	Jan. 31, 2019	Sep. 30, 2018	Feb. 28, 2017	Jun. 30, 2018	Sep. 30, 2017	Jun. 30, 2017	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Collaborative Agreements
Payment for debt extinguishment										$ 0	$ 28,054,000	$ 625,000
Shares issued in connection with Endoceutics License Agreement												13,500,000
Velo Bio, LLC
Collaborative Agreements
Payments related to collaborative arrangement				$ 12,500,000
Velo Bio, LLC | Regulatory Milestone Achievement
Collaborative Agreements
Milestone payments				5,000,000.0
Velo Bio, LLC | Regulatory Milestone Achievement, U.S.Food and Drug Administration Approval
Collaborative Agreements
Milestone payments				30,000,000.0
Velo Bio, LLC | Annual Sales Milestone Achievements
Collaborative Agreements
Milestone payments				240,000,000.0
Velo Bio, LLC | Annual Sales Milestone Achievements | Minimum
Collaborative Agreements
Sales milestone targets				300,000,000.0
Velo Bio, LLC | Annual Sales Milestone Achievements | Maximum
Collaborative Agreements
Sales milestone targets				900,000,000.0
Velo Bio, LLC | Commercial Milestone Payments
Collaborative Agreements
Milestone payments				$ 10,000,000.0
Endoceutics, Inc.
Collaborative Agreements
Consideration recorded								$ 83,500,000
Payments related to collaborative arrangement		$ 50,000,000.0
Number of shares issued under arrangement		600,000
Shares issued in connection with Endoceutics License Agreement		$ 13,500,000								0	0	12,555,000
Future contingent payments (up to)										0	$ 0	$ 9,300,000
IPR&D expense								5,800,000
Palatin Technologies, Inc.
Collaborative Agreements
Payments related to collaborative arrangement					$ 60,000,000.0
Out-of-pocket expenses (up to)					25,000,000.0
Intrarosa | Endoceutics, Inc. | Developed technology rights
Collaborative Agreements
Finite-lived intangible assets								$ 77,700,000
Intrarosa | Endoceutics, Inc. | Sales Milestones Achievement
Collaborative Agreements
Future contingent payments (up to)		895,000,000.0
Intrarosa | Endoceutics, Inc. | First Sales Milestone Achievement
Collaborative Agreements
Potential milestone payment, triggering event, sales		150,000,000.0
Future contingent payments (up to)		$ 15,000,000.0
Intrarosa | Endoceutics, Inc. | Delivery of Intrarosa Launch Quantities
Collaborative Agreements
Payments related to collaborative arrangement							$ 10,000,000.0
Intrarosa | Endoceutics, Inc. | First Anniversary of Closing
Collaborative Agreements
Future contingent payments (up to)										10,000,000.0
Intrarosa | Endoceutics, Inc. | Tiered Royalties
Collaborative Agreements
Royalty percentage, maximum		25.00%
Vyleesi Products | Palatin Technologies, Inc. | First Sales Milestone Achievement
Collaborative Agreements
Potential milestone payment, triggering event, sales					250,000,000.0
Future contingent payments (up to)					25,000,000.0
Vyleesi Products | Palatin Technologies, Inc. | Regulatory Milestone Achievement, Acceptance by U.S.Food And Drug Administration of New Drug Application
Collaborative Agreements
Payments related to collaborative arrangement						$ 20,000,000.0			$ 60,000,000.0
Vyleesi Products | Palatin Technologies, Inc. | Achievement of Certain Annual Sales Milestones Over Course of License Agreement
Collaborative Agreements
Future contingent payments (up to)					$ 300,000,000.0
Perosphere Pharmaceuticals Inc.
Collaborative Agreements
Consideration recorded	$ 50,000,000.0
Payments of asset acquisitions	40,000,000.0
Cancellation of convertible note	10,000,000.0
Other liabilities	6,200,000
Cash consideration	$ 60,800,000
Discount rate	34.00%
Contingent consideration (up to)			$ 365,000,000.0
Perosphere Pharmaceuticals Inc. | Regulatory Milestone Achievement
Collaborative Agreements
Contingent consideration (up to)			$ 140,000,000.0
Credited percentage			50.00%
Perosphere Pharmaceuticals Inc. | Milestone Achievement, Approval By European Medicines Agency
Collaborative Agreements
Contingent consideration (up to)			$ 40,000,000.0
Perosphere Pharmaceuticals Inc. | Sales Milestones Achievement
Collaborative Agreements
Contingent consideration (up to)			225,000,000.0
Perosphere Pharmaceuticals Inc. | First Sales Milestone Achievement
Collaborative Agreements
Contingent consideration, milestone payment			20,000,000.0
Potential milestone payment, triggering event, sales			$ 100,000,000.0
Perosphere Convertible Note | Convertible Debt | Perosphere Pharmaceuticals Inc.
Collaborative Agreements
Principal amount of debt at time of issuance	$ 10,000,000.0
Perosphere Term Loan | Line of Credit | Perosphere Pharmaceuticals Inc.
Collaborative Agreements
Payment for debt extinguishment	$ 12,000,000.0
Failure To Supply A Certain Percentage Of Product | Prasco, LLC
Collaborative Agreements
Failure to supply, penalties										$ 3,500,000